SenzaGen AB Sustainability Reports
SenzaGen AB develops and commercializes high-performance, non-animal in vitro test methods for assessing the allergenic and sensitizing potential of chemical substances. Its proprietary GARD platform utilizes genomics and machine learning to replace traditional laboratory animal testing for cosmetics, chemicals, and pharmaceuticals.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300SHQUZ0VQR2S848
FIGI: BBG00HMKSQS5
14 reports from 2017 to 2025
